On Apr 10, 2017, The Federal Circuit ruled that Sun Pharma did not infringe Takeda's blockbuster
anti-ulcer drug Prevacid (Lansoprazole) with a planned generic version
of the dissolving tablets & AFFIRMED the decision of New Jersey federal
court.
Sun submitted to FDA ANDA No. 206013 for seeking approval to
engage in the commercial manufacture, use and sale of lansoprazole delayed
release orally disintegrating tablets, 15 and 30 mg, prior to the expiration of
the patent-in-suit.
On Jul 06, 2016, New Jersey court Pursuant to the
Stipulation and Order entered final Judgment of Non-infringement Based on
Court's Claim Construction entered on June 9, 2016.
Without explaining its reasoning, a three-judge panel upheld
the lower court’s decision of non-infringement.
No comments:
Post a Comment